HETERODIMERIC ANTIBODIES THAT BIND CLAUDIN18.2 AND CD3

The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Claudin18.2 (CLDN18.2). La présente invention concerne des anticorps, comprenant de nouveaux domaines de liaison à l'antigène et des anticorps hétérodimères, qui se l...

Full description

Saved in:
Bibliographic Details
Main Authors BERNETT, Matthew, NISTHAL, Alex, MOORE, Gregory
Format Patent
LanguageEnglish
French
Published 22.12.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Claudin18.2 (CLDN18.2). La présente invention concerne des anticorps, comprenant de nouveaux domaines de liaison à l'antigène et des anticorps hétérodimères, qui se lient à la claudine 18.2 (CLDN18.2).
Bibliography:Application Number: WO2022US33625